Another study of 21 patients with lung, gastric, or bladder cancer who underwent anti-PD-1 therapy found that a reduction in plasma sPD-L1 levels is significantly correlated with tumor size reduction48. This evidence concerns the gene SPDL1 and urinary bladder cancer.